IRON
Disc Medicine, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 12 ▲ Disc Medicine announced updated Phase 2 data for DISC-0974 in myelof…
- Jul 7 to Jul 13 ▼ 2 days of insider sells: $2.5M by 2 insiders, avg $74.99
- Aug 6 to Sep 11 ▼ 10 days of insider sells: $10.2M by 4 insiders, avg $78.03
- Oct 19 to Oct 21 ▼ 3 days of insider sells: $3.4M by 1 insider, avg $80.13
- Oct 19 ▲ Disc Medicine announced overwhelmingly positive topline results from…
- Oct 21 ▼ Disc Medicine priced a $450M public offering of 6,000,000 shares at…
- Oct 22 ▼ Disc Medicine completed a $450M upsized public offering of 6M shares…
- Oct 24 Trial readout: Results Pending: DISC-1459 (Phase 3), Completed 46d ago
- Nov 4 FDA: Disc Medicine Announces Multiple Presentations Across Port…
- Nov 5 ▲ Disc Medicine reported Q3 2026 results with a net loss of $59.5M ($1…
- Nov 9 Guggenheim initiates
- Nov 10 ▼ 1 insider sell $1.4M at $85.09
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $17.4M.
- InstitutionsBULLISH
Q3 2026: 27 added (0 new), 8 trimmed or exited.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$1.812 → −$1.512 over 90 days. 4 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest −8.0% to 6.86M shares. 3.2 days to cover, ≈15.1% of shares.
- TrendUPTREND
12% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Assenagon Asset Management S.A. | DOUBLED | $73.3M |
| Aberdeen Group plc | ADD | $39.1M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $17.8M |
| JANE STREET GROUP, LLC | DOUBLED | $16.1M |
| Qube Research & Technologies Ltd | DOUBLED | $9.0M |
| Nuveen, LLC | DOUBLED | $8.7M |
| Pictet Asset Management Holding SA | TRIM | $8.3M |
| MORGAN STANLEY | ADD | $7.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +59%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Guggenheim INITIATE | Buy |
| Nov 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 20, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 20, 2026 | Truist Securities MAINTAIN | Buy |
| Oct 20, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 20, 2026 | Wedbush MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Savage William Jacob Chief Medical Officer Nov 10, 2026 | SELL | $1.4M |
Bitterman Kevin Director Oct 21, 2026 | SELL | $1.1M |
Bitterman Kevin Director Oct 21, 2026 | SELL | $920.2K |
Bitterman Kevin Director Oct 21, 2026 | SELL | $21.3K |
Bitterman Kevin Director Oct 20, 2026 | SELL | $229.4K |
Bitterman Kevin Director Oct 20, 2026 | SELL | $190.9K |
Bitterman Kevin Director Oct 20, 2026 | SELL | $4.4K |
Bitterman Kevin Director Oct 19, 2026 | SELL | $474.8K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.51 | -$1.71–-$1.36 | +12.9% | $0.00 |
| Next Q | -$1.63 | -$1.91–-$1.45 | +10.8% | $0.00 |
| Current FY | -$6.03 | -$6.44–-$5.11 | +8.1% | $0.00 |
| Next FY | -$6.25 | -$7.05–-$5.56 | +11.7% | $43.2M |
Washington
Short side
FINRA· Oct 30, 2026| Oct 19, 2026 | Resumption Scheduled | Resumed |
SecBot reports
35 filings · 8 press releases · 5 bullish · 7 bearish · 23 neutral- NEUTRAL 144Nov 10, 2026
William Savage, an officer of Disc Medicine, filed a Form 144 notice of intent to sell 16,035…
The filing is an advance notice of intent to sell; the actual sale may or may not occur. Monitor subsequent Form 4 filings to confirm execution and assess whether this is part of a broader insider…
- BEARISH 424B5Nov 5, 2026
Disc Medicine filed a prospectus supplement for an at-the-market (ATM) equity offering of up to…
The ATM adds a further capital-raising mechanism on top of the recent large October offering, signaling ongoing cash needs for clinical development and potential commercialization. Monitor actual…
- NEUTRAL 8-KNov 5, 2026
The company highlighted positive Phase 3 APOLLO data for bitopertin in EPP and plans NDA…
Monitor the NDA resubmission for bitopertin by end of 2026 and the FDA decision timeline to mid-2027. The end-of-phase 2 meeting for selcodebart in anemia of MF and updated data from RESTORE-PV at…
- BULLISH PRESS-RELEASENov 5, 2026
Disc Medicine reported Q3 2026 results with a net loss of $59.5M ($1.53 per share), narrower than…
The successful Phase 3 APOLLO trial is the primary catalyst, with NDA resubmission by year-end and FDA decision by mid-2027. Watch for the end-of-Phase 2 FDA meeting for selcodebart in anemia of MF…
All IRON filing & press-release reports (43)
- 144 reportNov 10, 2026
- 424B5 reportNov 5, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- PRESS-RELEASE reportNov 4, 2026
- INST-CLUSTER reportNov 3, 2026
- SC 13D/A reportOct 26, 2026
- 8-K reportOct 22, 2026
- 424B5 reportOct 21, 2026
- 144 reportOct 21, 2026
- 144 reportOct 21, 2026
- 144 reportOct 21, 2026
- 144 reportOct 20, 2026
- 144 reportOct 20, 2026
- 144 reportOct 20, 2026
- 424B5 reportOct 19, 2026
- 144 reportOct 19, 2026
- 144 reportOct 19, 2026
- 144 reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- 8-K reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- PRESS-RELEASE reportOct 18, 2026
- 8-K reportSep 10, 2026
- PRESS-RELEASE reportSep 9, 2026
- CLUSTER reportSep 3, 2026
- 144 reportSep 2, 2026
- CLUSTER reportAug 26, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportAug 14, 2026
- PRESS-RELEASE reportJul 30, 2026
- 8-K reportJul 30, 2026
- CLUSTER reportJul 14, 2026
- 8-K reportJun 30, 2026
- CLUSTER reportJun 30, 2026
- 144 reportJun 18, 2026
- PRESS-RELEASE reportJun 12, 2026
- PRESS-RELEASE reportJun 9, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 5, 2026
- CLUSTER reportApr 13, 2026
- 8-K reportFeb 26, 2026